Fennel Oil/Foeniculum vulgare / selectivity Cancer Research Results

FEO, Fennel Oil/Foeniculum vulgare: Click to Expand ⟱
Features:

fennel essential oil has major constituents commonly include trans-anethole, fenchone, estragole, limonene, and cis-anethole, and the proportions vary substantially by source, geography, and chemotype. One composition study found trans-anethole ranging 34.8–82.0%, fenchone 1.6–22.8%, estragole 2.4–17.0%, and limonene 0.8–16.5%. Another study found even wider variation, with estragole(toxic) reported up to 66% in some fennel oils.

Fennel oil — the volatile essential oil distilled primarily from the ripe fruits of Foeniculum vulgare Mill. It is a variable botanical mixture rather than a single pharmacological agent and is formally classified as a plant-derived essential oil or phytochemical mixture. Standard abbreviations include FEO and FVO. Trans-anethole is usually the dominant constituent, with fenchone, estragole, limonene, α-pinene and smaller terpenoids present in chemotype-dependent proportions. Sweet fennel oil is generally richer in trans-anethole and lower in fenchone than bitter fennel oil. Biological effects cannot be assigned uniformly across products because constituent concentrations, especially estragole, vary substantially.

Primary mechanisms (ranked):

  1. Mitochondrial and lysosomal membrane disruption with Bax/Bcl-2 shifting, caspase-9 and caspase-3 activation, PARP cleavage and apoptotic cell death, principally demonstrated for trans-anethole and selected fennel-oil preparations.
  2. Suppression of NF-κB-dependent survival and inflammatory signaling, including inhibition of TNF-induced NF-κB activation and downstream anti-apoptotic responses.
  3. Inhibition of cancer-cell proliferation through cell-cycle arrest and reduced clonogenic or tumorsphere-forming capacity.
  4. ROS elevation and oxidative stress in susceptible cancer cells, contributing to DNA damage, mitochondrial permeabilization, apoptosis and, in some models, autophagy.
  5. Suppression of migration, invasion and cancer stem-like phenotypes in prostate, breast and oral cancer models.
  6. Chemosensitization to cisplatin in preclinical models through increased apoptosis and reduced survival signaling.
  7. Anti-inflammatory and antioxidant effects in non-malignant tissues, including reduced inflammatory cytokine signaling; these effects are context-dependent and may oppose the pro-oxidant mechanism observed in cancer cells.

Bioavailability / PK relevance: Fennel oil is lipophilic, volatile and compositionally variable. Trans-anethole is absorbed and extensively metabolized by side-chain oxidation, with urinary elimination dominated by 4-methoxyhippuric acid. At low dietary exposures, detoxification predominates; high continuous exposures can shift metabolism toward potentially hepatotoxic intermediates. Oral anticancer exposure, tumor distribution and a validated therapeutic plasma concentration have not been established. Encapsulation may improve stability and delivery, but remains experimental.

In-vitro vs systemic exposure relevance: Most anticancer findings use concentrated essential oil or trans-anethole at micromolar concentrations, often approximately 50–200 µM, or essential-oil concentrations measured in µg/mL. These exposures are substantially higher than ordinary dietary exposure and have not been shown to be safely achievable in human tumors. Fennel tea, culinary seed intake and aromatherapy should not be treated as pharmacokinetically equivalent to concentrated essential oil.

Clinical evidence status: Preclinical only for cancer treatment. Evidence consists mainly of cancer-cell studies, limited animal experiments and mechanistic studies of trans-anethole. There are no established randomized oncology trials, approved anticancer indications or validated clinical dosing regimens for fennel oil. Traditional herbal deployment is directed mainly toward mild gastrointestinal or respiratory symptoms rather than cancer. Concentrated internal use is constrained by estragole exposure, product heterogeneity, allergy risk and inadequate long-term safety data.

Fennel Oil Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Lipophilic membrane stress Viability ↓; membrane integrity ↓; morphology altered Potential membrane irritation at high exposure G Weak-to-moderate cytotoxicity Core essential-oil mechanism; requires high in-vitro concentrations and depends strongly on oil composition.
2 Mitochondrial ROS and oxidative stress signaling ROS ↑; JNK/c-Jun ↑; stress proteins ↑ Antioxidant or anti-inflammatory effects may occur in non-cancer models R/G Stress-amplified apoptosis Most convincing in TNBC cell data using Foeniculum vulgare subsp. piperitum oil; antioxidant rescue supports ROS involvement.
3 NRF2 stress-response activation NRF2 ↑; HO-1 ↑; NQO1 ↑ Potential cytoprotection ↑ (context-dependent) G Adaptive stress response plus apoptosis coupling In cancer cells, NRF2 activation appears secondary to ROS stress and coexists with apoptosis; not necessarily a purely protective effect.
4 p53 DNA damage apoptosis axis p53-axis ↑; γH2AX ↑; caspase-3 ↑; PARP cleavage ↑ Genotoxic-risk concern if estragole exposure is substantial G Apoptotic cell death Mechanistically relevant for anticancer interpretation, but safety interpretation is complicated by DNA-reactive estragole metabolism.
5 Cell-cycle and proliferation markers Cell-cycle arrest ↑; Ki-67 ↓; Bcl-2 ↓; miR-21 ↓; miR-92a ↓ Limited toxicity in tested lymphocytes in one oil-mixture model G Growth arrest and apoptosis Evidence is partly from fennel plus geranium oil mixtures, so attribution to fennel oil alone is uncertain.
6 Survivin mitochondrial apoptosis axis Survivin ↓; mitochondrial toxicity ↑; caspase-3 ↑ Normal liver-cell toxicity ↔ in seed-extract model G Apoptosis sensitization Relevant to Foeniculum vulgare seed extract rather than essential oil specifically; useful as genus-level support but not direct FEO evidence.
7 Inflammatory cytokine suppression Indirect tumor relevance only IL-6 ↓; TNF-α ↓; IL-1β ↓; inflammation ↓ G Anti-inflammatory modulation Better supported in normal inflammatory models than in tumor microenvironment models.
8 TRPA1 activation Unclear; context-dependent Ca²⁺ signaling possible TRPA1 ↑; sensory/neurogenic signaling possible R Ion-channel agonism Mechanistically specific for trans-anethole, but not yet a primary anticancer axis for fennel oil.
9 Estragole bioactivation and genotoxicity DNA adduct risk ↑; carcinogenic liability ↑ DNA-reactive metabolite risk ↑ G Safety constraint This is a negative translational feature. Estragole-rich oils should not be interpreted as desirable anticancer products.
10 Clinical Translation Constraint High in-vitro concentrations; chemotype heterogeneity; no oncology RCTs Estragole exposure, irritation, sensitization, pregnancy and pediatric constraints G Limits clinical relevance For database purposes, FEO should be marked preclinical and composition-dependent, with estragole content as a required safety note.

P: 0–30 min

R: 30 min–3 hr

G: >3 hr
selectivity, selectivity: Click to Expand ⟱
Source:
Type:
The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues.

Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance

Factors that affect selectivity:
1. Ability of Cancer cells to preferentially absorb a product/drug
-EPR-enhanced permeability and retention of cancer cells
-nanoparticle formations/carriers may target cancer cells over normal cells
-Liposomal formations. Also negatively/positively charged affects absorbtion

2. Product/drug effect may be different for normal vs cancer cells
- hypoxia
- transition metal content levels (iron/copper) change probability of fenton reaction.
- pH levels
- antiOxidant levels and defense levels

3. Bio-availability
Scientific Papers found: Click to Expand⟱
6426- FEO,    Foeniculum Vulgare and Pelargonium Graveolens Essential Oil Mixture Triggers the Cell Cycle Arrest and Apoptosis in MCF-7 Cells
- in-vitro, BC, MCF7
TumCCA↑, Apoptosis↓, selectivity↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

selectivity↑, 1,  
Total Targets: 3

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: selectivity, selectivity
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:404  Target#:1110  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page